RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $76
RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:PCRX) with a Outperform and lowers the price target from $80 to $76.
LIVE: Biden Speaks On Suspected Chinese Spy Balloon
https://www.youtube.com/watch?v=AJjkzjm-8-Q
Related Posts
Why B2B Rental Company McGrath RentCorp Shares Are Surging Premarket Monday
McGrath RentCorp (NASDAQ: MGRC) sees a 9.62% surge as WillScot Mobile Mini's $3.8 billion acquisition deal unfolds. McGrath shareholders to choose between $123.00 cash or 2.8211 WillScot Mobile Mini shares, impacting 60% in cash and 40% in stocks. The strategic move aims to enhance WillScot's North American leadership in turnkey space solutions.
Shark Tank’s Kevin O’Leary Slams Crypto Exchanges For Suing Regulators: ‘Stupid Idea’
Shark Tank star Kevin O’Leary, on Tuesday, said that cryptocurrency exchanges should not be pursuing legal action against…
Pushing Rivalry Aside: Elon Musk And Jeff Bezos Agree On How Good This Streaming Show Is
A rivalry between two of the richest people in the world has escalated over the years due to their respective space companies.